-
2023-505615-21-00
5
2021-04-28
Muscle Invasive Bladder Cancer
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-506498-36-00
5
2021-04-08
Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
2023-506962-30-00
5
2021-03-29
Non-alcoholic steatohepatitis (NASH)
-
2023-506526-37-00
5
2021-03-17
Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
2023-507418-28-00
4
2021-03-15
Solid tumors
-
2023-508504-38-00
5
2021-03-01
Obesity
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-504959-27-00
5
2020-12-09
Participants with Limited Stage-Small Cell Lung Cancer, who have recei
-
2023-506911-16-00
5
2020-12-04
ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
-
2022-502611-10-00
5
2020-11-24
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-506515-18-00
5
2020-10-23
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-506033-29-00
5
2020-10-09
EGFR Exon 20ins Mutated Locally
Advanced or Metastatic Non-Small Cell
-
2023-506576-27-00
5
2020-09-30
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2022-501012-34-00
5
2020-02-27
Pulmonary Arterial Hypertension
-
2022-501531-16-00
5
2020-01-24
esophageal carcinoma